PT - JOURNAL ARTICLE AU - Vasylyeva, Tetyana I. AU - Fang, Courtney E. AU - Su, Michelle AU - Havens, Jennifer L. AU - Parker, Edyth AU - Wang, Jade C. AU - Zeller, Mark AU - Yakovleva, Anna AU - Hassler, Gabriel W. AU - Chowdhury, Moinuddin A. AU - Andersen, Kristian G. AU - Hughes, Scott AU - Wertheim, Joel O. TI - Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early 2021 AID - 10.1101/2022.04.15.22273909 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.15.22273909 4099 - http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273909.short 4100 - http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273909.full AB - Background Monitoring the emergence and spread of SARS-CoV-2 variants is an important public health objective. Travel restrictions, aimed to prevent viral spread, have major economic consequences and unclear effectiveness despite considerable research. We investigated the introduction and establishment of the Gamma variant in New York City (NYC) in 2021.Methods We performed phylogeographic analysis on 15,967 Gamma sequences available on GISAID and sampled between March 10th through May 1st, 2021, to identify geographic sources of Gamma lineages introduced into NYC. We identified locally circulating Gamma transmission clusters and inferred the timing of their establishment in NYC.Findings We identified 16 phylogenetically-distinct Gamma clusters established in NYC (cluster sizes ranged 2-108 genomes). Most of the NYC clusters were introduced from Florida and Illinois; only one was introduced from outside the United States (US). By the time the first Gamma case was reported by genomic surveillance in NYC on March 10th, the majority (57%) of circulating Gamma lineages had already been established in the city for at least two weeks.Interpretation Despite the expansion of SARS-CoV-2 genomic surveillance in NYC, there was a substantial gap between Gamma variant introduction and establishment in January/February 2021, and its identification by genomic surveillance in March 2021. Although travel from Brazil to the US was restricted from May 2020 through the end of the study period, this restriction did not prevent Gamma from becoming established in NYC as most introductions occurred from domestic locations.Competing Interest StatementK.G.A. has received consulting fees for advising on SARS-CoV-2, variants, and the COVID-19 pandemic. J.O.W. has received funding from the CDC (ongoing) via contracts and agreements to his institution unrelated to this research.Funding StatementT.I.V. is funded by a Branco Weiss Fellowship. J.O.W. acknowledges funding from the National Institutes of Health (AI135992). G.W.H. acknowledges funding from the National Institutes of Health (AI154824). K.G.A acknowledges funding from the National Institutes of Health (U01AI151812 and U19AI135995) and CDC BAA contract 75D30120C09795. This work was supported (in part) by the Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases Cooperative Agreement (Grant Number: ELC DETECT (6NU50CK000517-01-07) funded by the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of UC San Diego waived ethical approval of this work as human subjects except.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the analyses are available though GISAID (https://www.gisaid.org/).